^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

lerapolturev (PVS-RIPO)

i
Other names: PVS-RIPO, PVSRIPO, recombinant polio virus vaccine, polio virus sabin-rhinovirus poliovirus, re-engineered poliovirus, sabin type 1 polio vaccine
Company:
Istari Oncology
Drug class:
Immunostimulant, Dendritic cell activator
Related drugs:
29d
LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors (clinicaltrials.gov)
P1/2, N=4, Terminated, Istari Oncology, Inc. | N=15 --> 4 | Trial completion date: May 2025 --> Jun 2024 | Recruiting --> Terminated | Trial primary completion date: May 2025 --> Apr 2024; business decision
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Checkpoint inhibition • Pan tumor • Metastases
|
lerapolturev (PVS-RIPO)
2ms
LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma (clinicaltrials.gov)
P2, N=56, Active, not recruiting, Istari Oncology, Inc. | Trial primary completion date: Jun 2024 --> Oct 2024
Trial primary completion date • Checkpoint inhibition • IO biomarker • Checkpoint block • Metastases
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8)
|
PD-L1 expression • BRAF mutation • BRAF wild-type
|
lerapolturev (PVS-RIPO)
2ms
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients with Recurrent Glioblastoma (clinicaltrials.gov)
P2, N=25, Completed, Istari Oncology, Inc. | Active, not recruiting --> Completed | Trial completion date: Mar 2024 --> Jun 2024 | Trial primary completion date: Mar 2024 --> Jun 2024
Trial completion • Trial completion date • Trial primary completion date • Checkpoint inhibition • IO biomarker
|
Keytruda (pembrolizumab) • lerapolturev (PVS-RIPO)
2ms
PVSRIPO for Patients With Unresectable Melanoma (clinicaltrials.gov)
P1, N=12, Terminated, Istari Oncology, Inc. | Completed --> Terminated; Study closed to enrollment due to business decision prior to enrolling Cohort 4
Trial termination
|
BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • PVR (PVR Cell Adhesion Molecule)
|
BRAF mutation • BRAF wild-type • CD8 positive
|
lerapolturev (PVS-RIPO)
6ms
Lerapolturev (PVSRIPO) in GBM (clinicaltrials.gov)
P2, N=92, Not yet recruiting, Darell Bigner | Initiation date: Apr 2024 --> Jul 2024
Trial initiation date
|
lomustine • lerapolturev (PVS-RIPO)
8ms
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children (clinicaltrials.gov)
P1, N=8, Completed, Istari Oncology, Inc. | Active, not recruiting --> Completed | Phase classification: P1b --> P1 | N=12 --> 8
Trial completion • Phase classification • Enrollment change
|
NF1 (Neurofibromin 1)
|
NF1 mutation
|
lerapolturev (PVS-RIPO)
8ms
LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma (clinicaltrials.gov)
P2, N=56, Active, not recruiting, Istari Oncology, Inc. | Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Oct 2023 --> Jun 2024
Trial completion date • Trial primary completion date • Checkpoint inhibition • IO biomarker • Checkpoint block • Metastases
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8)
|
PD-L1 expression • BRAF mutation • BRAF wild-type
|
lerapolturev (PVS-RIPO)
9ms
Lerapolturev (PVSRIPO) in GBM (clinicaltrials.gov)
P2, N=92, Not yet recruiting, Darell Bigner | Initiation date: Dec 2023 --> Apr 2024
Trial initiation date
|
lomustine • lerapolturev (PVS-RIPO)
10ms
Examining Bioactivity of PVSRIPO in Invasive Breast Cancer (clinicaltrials.gov)
P1, N=5, Completed, Istari Oncology, Inc. | Recruiting --> Completed
Trial completion
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 amplification • HER-2 negative • HER-2 expression • ER expression • PGR expression
|
lerapolturev (PVS-RIPO)
11ms
Lerapolturev (PVSRIPO) in GBM (clinicaltrials.gov)
P2, N=92, Not yet recruiting, Darell Bigner
New P2 trial
|
lomustine • lerapolturev (PVS-RIPO)
over1year
Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial. (PubMed, Lancet Child Adolesc Health)
Convection enhanced delivery of lerapolturev is safe enough in the treatment of recurrent paediatric high-grade glioma to proceed to the next phase of trial.
P1 data • Clinical Trial,Phase I • Journal
|
PVR (PVR Cell Adhesion Molecule)
|
Avastin (bevacizumab) • lerapolturev (PVS-RIPO)
almost2years
LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma (clinicaltrials.gov)
P2, N=56, Recruiting, Istari Oncology, Inc. | Trial completion date: May 2023 --> Oct 2023 | Trial primary completion date: Apr 2023 --> Oct 2023
Trial completion date • Trial primary completion date • Checkpoint inhibition • IO biomarker • Checkpoint block • Metastases
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8)
|
PD-L1 expression • BRAF mutation
|
lerapolturev (PVS-RIPO)
2years
Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma. (PubMed, J Immunother Cancer)
An inflamed pretreatment tumor microenvironment, possibly induced by prior anti-PD-1 therapy and a proficient peripheral blood pretreatment innate immune response (antiviral/interferon signaling) to lerapolturev was associated with long term PFS after intratumoral lerapolturev in a small cohort of patients. These findings imply a link between intratumoral T cell inflammation and peripheral immune function.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • CCR7 (Chemokine (C-C motif) receptor 7)
|
lerapolturev (PVS-RIPO)
2years
CXCR3 signaling engages glioma infiltrating T cells and is required for the antitumor efficacy of innate stimulating immunotherapy (SNO 2022)
The capacity of relevant innate stimulating immunotherapies to induce CXCR3 ligands in human glioma tissue was assessed using an ex vivo glioma slice culture assay, and the contribution of CXCR3 signaling to polio virotherapy (PVSRIPO) and STING agonist therapy was tested in murine models... This work indicates that CXCR3 signaling, a key contributor to cancer immune surveillance, is disrupted in human gliomas relative to other solid tumor types. Intratumor virotherapy and STING agonists hold potential to rectify diminished CXCR3 ligand expression in gliomas.
Clinical • IO biomarker
|
CXCL9 (Chemokine (C-X-C motif) ligand 9) • CXCR3 (C-X-C Motif Chemokine Receptor 3)
|
lerapolturev (PVS-RIPO)
over2years
PVSRIPO for Patients With Unresectable Melanoma (clinicaltrials.gov)
P1, N=12, Completed, Istari Oncology, Inc. | Active, not recruiting --> Completed | N=18 --> 12
Trial completion • Enrollment change
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF wild-type
|
lerapolturev (PVS-RIPO)
over2years
LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma (clinicaltrials.gov)
P2, N=56, Recruiting, Istari Oncology, Inc. | Active, not recruiting --> Recruiting
Enrollment open • Checkpoint inhibition • IO biomarker
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8)
|
PD-L1 expression • BRAF mutation
|
lerapolturev (PVS-RIPO)
over2years
Enrollment closed
|
CD4 (CD4 Molecule)
|
PD-L1 expression • CDKN2A negative
|
PD-L1 IHC 22C3 pharmDx
|
lerapolturev (PVS-RIPO)
over2years
LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma (clinicaltrials.gov)
P2, N=56, Active, not recruiting, Istari Oncology, Inc. | Recruiting --> Active, not recruiting
Enrollment closed • Checkpoint inhibition • IO biomarker
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8)
|
PD-L1 expression • BRAF mutation
|
lerapolturev (PVS-RIPO)
almost3years
PVSRIPO for Patients With Unresectable Melanoma (clinicaltrials.gov)
P1, N=18, Active, not recruiting, Istari Oncology, Inc. | Trial completion date: Dec 2021 --> Apr 2022 | Trial primary completion date: Dec 2021 --> Mar 2022
Trial completion date • Trial primary completion date
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF wild-type
|
lerapolturev (PVS-RIPO)
3years
Polio virotherapy of murine brain tumors induces microglia proliferation and inflammation that is potentiated by immune checkpoint blockade (SNO 2021)
Immunotherapy with polio:rhinovirus recombinant (PVSRIPO) has shown evidence of efficacy in a phase I clinical trial for recurrent GBM, resulting in durable radiographic responses and 21% long-term survival at 36 months...Thus, buttressing type-I IFN directed antitumor CD8+T cell immunity, e.g. with blockade of the PD1:PD-L1 immune checkpoint, might contribute to tumor remission. Indeed, combination therapy with αPD-L1 antibody in the CT2A model showed longer median survival and higher long-term remission rate compared to monotherapy alone; CD8 T cell depletion can completely abrogate this efficacy with this therapy combination, confirming the role of anti-tumor immunity in this approach.
Preclinical • Checkpoint inhibition
|
CD8 (cluster of differentiation 8)
|
lerapolturev (PVS-RIPO)
3years
Intratumor childhood vaccine-specific CD4+ T cell recall helps antitumor CD8 T cells (SITC 2021)
Conclusions Childhood vaccine-specific CD4+ T cells hold cancer immunotherapy potential. In the context of PVSRIPO therapy, antitumor and inflammatory effects of polio vaccine-specific CD4+ T cell recall supersedes inhibitory effects of attenuated intratumor viral replication, and represents a novel mechanism of action.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CD4 (CD4 Molecule) • GZMB (Granzyme B)
|
IFNG expression
|
lerapolturev (PVS-RIPO)
over3years
Examining Bioactivity of PVSRIPO in Invasive Breast Cancer (clinicaltrials.gov)
P1, N=6, Recruiting, Istari Oncology, Inc. | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Jul 2021 --> Jul 2022
Clinical • Trial completion date • Trial primary completion date • Oncolytic virus
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 amplification • HER-2 negative • HER-2 expression • ER expression • PGR expression
|
lerapolturev (PVS-RIPO)
over3years
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children (clinicaltrials.gov)
P1b, N=12, Active, not recruiting, Istari Oncology, Inc. | Trial primary completion date: Jun 2021 --> Dec 2021
Clinical • Trial primary completion date
|
NF1 (Neurofibromin 1)
|
NF1 mutation
|
lerapolturev (PVS-RIPO)
over3years
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children (clinicaltrials.gov)
P1b, N=12, Active, not recruiting, Istari Oncology, Inc. | Recruiting --> Active, not recruiting
Clinical • Enrollment closed
|
NF1 (Neurofibromin 1)
|
NF1 mutation
|
lerapolturev (PVS-RIPO)
over3years
Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma. (PubMed, J Immunother Cancer)
Intratumoral PVSRIPO was well tolerated. Despite the limited number of PVSRIPO treatments relative to the overall lesion burden (67% patients>5 lesions), intratumoral PVSRIPO showed promising antitumor activity, with pCR in injected as well as non-injected lesions in select patients.
Clinical • P1 data • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
lerapolturev (PVS-RIPO)
over3years
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children (clinicaltrials.gov)
P1b, N=12, Recruiting, Istari Oncology, Inc. | Trial primary completion date: Mar 2021 --> Jun 2021
Clinical • Trial primary completion date
|
NF1 (Neurofibromin 1)
|
NF1 mutation
|
lerapolturev (PVS-RIPO)
almost4years
Persistent STAG2 mutation despite multimodal therapy in recurrent pediatric glioblastoma. (PubMed, NPJ Genom Med)
This report describes the genetic findings, obtained from whole-exome sequencing of a pediatric patient with glioblastoma who underwent multiple surgical resections and treatment with standard chemoradiation, as well as a novel recombinant poliovirus vaccine therapy...As such, this case represents a novel report following the clinical and genetic progression of a STAG2 mutated glioblastoma, including treatment with a novel and emerging immunotherapy. Although STAG2 deficiency comprises only a small subset of gliomas, this case adds clinical evidence to existing preclinical data supporting a role for STAG2 mutations in gliomagenesis and resistance to standard therapies.
Clinical • Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • STAG2 (Stromal Antigen 2)
|
EGFR mutation • BRAF mutation • PTPN11 mutation • BRAF D594G • STAG2 mutation
|
lerapolturev (PVS-RIPO)
almost4years
PVSRIPO for Patients With Unresectable Melanoma (clinicaltrials.gov)
P1, N=18, Active, not recruiting, Istari Oncology, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
Clinical • Enrollment closed • Trial completion date • Trial primary completion date
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
lerapolturev (PVS-RIPO)
almost4years
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children (clinicaltrials.gov)
P1b, N=12, Recruiting, Istari Oncology, Inc. | Trial completion date: Jul 2021 --> Mar 2022 | Trial primary completion date: Jul 2020 --> Mar 2021
Clinical • Trial completion date • Trial primary completion date
|
NF1 (Neurofibromin 1)
|
NF1 mutation
|
lerapolturev (PVS-RIPO)
almost4years
Clinical • Enrollment open • Combination therapy • Checkpoint inhibition • IO biomarker
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8)
|
PD-L1 expression • BRAF mutation
|
lerapolturev (PVS-RIPO)
4years
PVSRIPO for Patients With Unresectable Melanoma (clinicaltrials.gov)
P1, N=18, Recruiting, Istari Oncology, Inc. | N=12 --> 18
Clinical • Enrollment change
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
lerapolturev (PVS-RIPO)
4years
Clinical • New P2 trial • Combination therapy • Checkpoint inhibition • IO biomarker
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8)
|
PD-L1 expression • BRAF mutation
|
lerapolturev (PVS-RIPO)
over4years
PVSRIPO for Patients With Unresectable Melanoma (clinicaltrials.gov)
P1, N=12, Active, not recruiting, Istari Oncology, Inc. | Recruiting --> Active, not recruiting
Clinical • Enrollment closed
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
lerapolturev (PVS-RIPO)
almost5years
PVSRIPO in Combination With Nivolumab in Melanoma (clinicaltrials.gov)
P1, N=0, Withdrawn, Darell Bigner | N=30 --> 0 | Not yet recruiting --> Withdrawn
Clinical • Enrollment change • Trial withdrawal • Combination therapy
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF V600
|
Opdivo (nivolumab) • lerapolturev (PVS-RIPO)
almost5years
PVSRIPO in Combination With Nivolumab in Melanoma (clinicaltrials.gov)
P1, N=30, Not yet recruiting, Darell D. Bigner, MD, PhD | Initiation date: Dec 2019 --> Jun 2020
Clinical • Trial initiation date • Combination therapy
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF V600
|
Opdivo (nivolumab) • lerapolturev (PVS-RIPO)